PRACTICAL IMPLICATIONS
Guillain-Barré syndrome should be suspected in patients presenting with muscle weakness after COVID-19.
In December 2019, the first case of pneumonia with unknown etiology was reported in Wuhan city, China. The identified pathogen was a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 Since then, the virus has spread rapidly worldwide. Although coronavirus disease 2019 (COVID-19) typically presents with upper or lower respiratory symptoms, there have been rare reports of significant neurologic complications.2,3 Recently, a few reports presented cases of Guillain-Barré syndrome (GBS) after COVID-19.4,5 In this report, we describe 2 cases of GBS that occurred after COVID-19.
Case 1
In March 2020, a 46-year-old man came to the neurology clinic because of complaints of pain and numbness in distal lower and upper extremities for a week. In addition, progressive ascending weakness in legs had started 2 days back. The medical history revealed a history of low-grade fever, sore throat, dry cough, and mild dyspnea started 18 days before the first neurologic symptom onset. High-resolution chest CT scan (HRCT) at that time revealed multiple ground-glass opacities in peripheries of both lungs, typical for COVID-19, and the nasopharyngeal sample PCR confirmed the diagnosis. He had received hydroxychloroquine for 5 days. His respiratory symptoms improved after 10 days.
At the recent presentation, general physical examinations, including vital signs, were unremarkable. Neurologic examination revealed a mild peripheral facial nerve palsy on the right side. Muscles' forces were 4/5 in distal and proximal lower extremities according to the Medical Research Council (MRC) grading. The upper extremities showed no weakness. Deep tendon reflexes were absent in all 4 limbs. The electrodiagnostic study showed increased distal latencies in all 4 extremities. There was also symmetric nerve conduction slowing, suggestive of demyelinating polyneuropathy (table 1). An analysis of CSF revealed increased protein level (78 mg/dL, normal: 20–40 mg/dL), and normal cell counts (erythrocyte = 0/mm3, normal: 0–10/mm3; leukocyte = 4/mm3, normal: 0–5/mm3) and glucose level (70 mg/dL, normal: 45–80 mg/dL). Based on the clinical presentations and paraclinical findings, the diagnosis of GBS was established (table 2).
Electrodiagnostic Study Findings in Case 1 and Case 2
Laboratory and Examination Findings
During admission, upper limb forces decreased to the MRC grade of 4/5, and lower extremities' strength reduced to 3/5 in distal and 4/5 in proximal. The patient remained ambulatory and did not deteriorate more, so he received neither plasmapheresis nor intravenous immunoglobulin (IVIG). After 16 days of close monitoring, his muscle forces improved to near normal.
Case 2
In March 2020, a 65-year-old man presented with a progressive ascending lower and upper extremities weakness and paresthesia. His symptoms had started 4 days before the first visit. He also had a history of COVID-19 (confirmed by HRCT and nasopharyngeal sample PCR), which had started 10 days before his neurologic symptoms' onset. General physical examinations, including vital signs, were unremarkable except for fine crackles in both lungs. His neurologic examination showed decreased forces, MRC grade of 2/5 at proximal and 3/5 at distal lower limbs, and 4/5 in both arms. His deep tendon reflexes were absent in both legs and decreased to 1+ in the upper extremities.
His electrodiagnostic study revealed generalized increased distal latencies and absent F waves (table 1). As the findings were indicative of GBS (table 2), he received a course of IVIG. On the discharge day (day +14), his muscle forces were MRC grade 4/5 in all extremities.
Discussion
We described 2 cases of GBS occurring several days after COVID-19. There are rare reported cases of GBS in association with coronaviruses other than COVID-19. In 2017, a case series presented 4 patients infected with the Middle East Respiratory syndrome Coronavirus who presented with symptoms suggestive of GBS.6 However, they did not report nerve conduction data and assumed intensive-care-unit neuropathy as a differential diagnosis.
One of the suggested mechanisms for the development of GBS is the molecular resemblance. An immune response triggered by previous infection cross-reacts with the peripheral nerve myelin sheath and causes its damage. Some viruses are known to be associated with GBS. These include the human influenza virus, cytomegalovirus, HIV, and Epstein-Barr virus.7
Our presented cases and also other recently published reports4,5 suggest that the SARS-CoV-2 might trigger GBS.
In a pandemic situation, physicians should be aware of the risk of acute demyelinating polyneuropathy after COVID-19. Because the COVID-19 is extremely contagious, we suggest that the physicians evaluate newly diagnosed patients with GBS for this infection as a potential trigger.
Study Funding
No targeted funding reported.
Disclosure
The authors report no disclosures relevant to the manuscript. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Appendix Authors
Footnotes
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
- Received April 27, 2020.
- Accepted May 15, 2020.
- © 2020 American Academy of Neurology
The Nerve!: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.